These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

337 related items for PubMed ID: 18158020

  • 1. The safety and efficacy of different doses of bacillus Calmette Guérin in superficial bladder transitional cell carcinoma.
    Agrawal MS, Agrawal M, Bansal S, Agarwal M, Lavania P, Goyal J.
    Urology; 2007 Dec; 70(6):1075-8. PubMed ID: 18158020
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Sequential bacillus Calmette-Guerin and epirubicin versus bacillus Calmette-Guerin alone for superficial bladder tumors: a randomized prospective study.
    Ali-El-Dein B, Nabeeh A, Ismail EH, Ghoneim MA.
    J Urol; 1999 Aug; 162(2):339-42. PubMed ID: 10411034
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. [Bacillus Calmette Guerin as adjuvant treatment for superficial bladder tumors using two different therapeutic schemes].
    Iturralde Codina A, Beyríe Tamayo W, Gozá León F, Muñoz YI.
    Arch Esp Urol; 2004 Aug; 57(6):606-18. PubMed ID: 15382436
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. [Clinical investigation on the effect of intravesical instillation of antifibrinolytic agents with bacillus Calmette-Guerin on preventing bladder cancer recurrence].
    Ding GQ, Shen ZJ, Lu J, Jin XD, Chen J, Shi SF.
    Zhonghua Wai Ke Za Zhi; 2005 Nov 15; 43(22):1457-60. PubMed ID: 16318813
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A multicentre, randomised prospective trial comparing three intravesical adjuvant therapies for intermediate-risk superficial bladder cancer: low-dose bacillus Calmette-Guerin (27 mg) versus very low-dose bacillus Calmette-Guerin (13.5 mg) versus mitomycin C.
    Ojea A, Nogueira JL, Solsona E, Flores N, Gómez JM, Molina JR, Chantada V, Camacho JE, Piñeiro LM, Rodríguez RH, Isorna S, Blas M, Martínez-Piñeiro JA, Madero R, CUETO Group (Club Urológico Español De Tratamiento Oncológico).
    Eur Urol; 2007 Nov 15; 52(5):1398-406. PubMed ID: 17485161
    [Abstract] [Full Text] [Related]

  • 10. The effect of ofloxacin on bacillus calmette-guerin induced toxicity in patients with superficial bladder cancer: results of a randomized, prospective, double-blind, placebo controlled, multicenter study.
    Colombel M, Saint F, Chopin D, Malavaud B, Nicolas L, Rischmann P.
    J Urol; 2006 Sep 15; 176(3):935-9. PubMed ID: 16890660
    [Abstract] [Full Text] [Related]

  • 11. Urinary Interleukin-8 and 18 predict the response of superficial bladder cancer to intravesical therapy with bacillus Calmette-Guerin.
    Thalmann GN, Sermier A, Rentsch C, Möhrle K, Cecchini MG, Studer UE.
    J Urol; 2000 Dec 15; 164(6):2129-33. PubMed ID: 11061941
    [Abstract] [Full Text] [Related]

  • 12. Long-term efficacy of maintenance bacillus Calmette-Guérin versus maintenance mitomycin C instillation therapy in frequently recurrent TaT1 tumours without carcinoma in situ: a subgroup analysis of the prospective, randomised FinnBladder I study with a 20-year follow-up.
    Järvinen R, Kaasinen E, Sankila A, Rintala E, FinnBladder Group.
    Eur Urol; 2009 Aug 15; 56(2):260-5. PubMed ID: 19395154
    [Abstract] [Full Text] [Related]

  • 13. Twelve-year follow up of a randomized prospective trial comparing bacillus Calmette-Guerin and epirubicin as adjuvant therapy in superficial bladder cancer.
    Cheng CW, Chan SF, Chan LW, Chan CK, Ng CF, Cheung HY, Chan SY, Wong WS, Lai FM, To KF, Li ML.
    Int J Urol; 2005 May 15; 12(5):449-55. PubMed ID: 15948743
    [Abstract] [Full Text] [Related]

  • 14. High grade superficial (G3t1) transitional cell carcinoma of the bladder treated with intravesical Bacillus Calmette-Guerin (BCG).
    Pansadoro V, Emiliozzi P, depaula F, Scarpone P, Pizzo M, Federico G, Martini M, Pansadoro A, Sternberg CN.
    J Exp Clin Cancer Res; 2003 Dec 15; 22(4 Suppl):223-7. PubMed ID: 16767936
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Can intravesical bacillus Calmette-Guérin reduce recurrence in patients with superficial bladder cancer? A meta-analysis of randomized trials.
    Han RF, Pan JG.
    Urology; 2006 Jun 15; 67(6):1216-23. PubMed ID: 16765182
    [Abstract] [Full Text] [Related]

  • 19. Sustained prophylactic effect of intravesical bacille Calmette-Guérin for superficial bladder cancer: a smoothed hazard analysis in a randomized prospective study.
    Hinotsu S, Akaza H, Isaka S, Kanetake H, Kubota Y, Kuroda M, Shinohara N, Shinka T, Tachibana M, Naito S, Hirao Y, BCG Tokyo 172 Strain Study Group.
    Urology; 2006 Mar 15; 67(3):545-9. PubMed ID: 16527576
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.